Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blood clot drug ease arthritis pain?

NCT ID NCT05671497

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether cilostazol, a drug normally used for leg pain from blocked arteries, can help control rheumatoid arthritis when added to standard medications. 70 adults with moderate to severe arthritis took either cilostazol plus their usual drugs or just their usual drugs for 6 months. The goal was to see if cilostazol reduces joint swelling, pain, and inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cilostazol
What this could lead to
If it works, this could point toward a new, affordable add-on treatment to better control rheumatoid arthritis symptoms.
What could go wrong
This is a small, completed Phase 2/3 trial with only 70 participants. Results may not apply to all patients, and cilostazol can cause side effects like headache or heart issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

70 people

The number who actually took part.

Started

Nov 2022

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients. (\>18 years old). 2. Moderate to high disease activity (DAS28-CRP\>3.2). 3. Patients receiving stable cDMARD regimen for at least 3 months before inclusion in the study. Exclusion Criteria: 1. Hypersensitivity to cilostazol. 2. Heart failure. 3. Pregnant and lactating women. 4. Patients with liver impairment (ALT or AST \> 3\* ULN). 5. Patients with renal impairment (CrCl\<60 mL/min). 6. Patients receiving any other antiplatelet or anticoagulant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • Al-Zahraa Hospital

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.